Genentech, a member of the Roche Group (RHHBY), announced its decision to advance prasinezumab—a potential anti-alpha-synuclein antibody—into Phase III clinical development for early-stage Parkinson's disease. The decision is based on findings from the Phase IIb PADOVA study, as well as ongoing open-label extensions (OLEs) of both the PADOVA and Phase II PASADENA trials.
The ongoing PASADENA and PADOVA open-label extension (OLE) studies are evaluating the long-term safety and efficacy of prasinezumab in more than 750 individuals with early-stage Parkinson's disease.
Roche's Genentech entered into a Licensing, Development, and Commercialization agreement with Prothena in December 2013 to develop and commercialize monoclonal antibodies targeting aggregated alpha-synuclein, such as prasinezumab, for the treatment of Parkinson's disease.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.